巨头关闭疫苗部门？多家知名药企大幅裁员

虎嗅网2023-08-24

8月23日，美国癌症免疫疗法公司Agenus 宣布计划裁员25%，并大幅缩减癌症药物研究。就在同一天，有报道称，强生旗下的杨森制药打算关闭位于荷兰莱顿的传染病和疫苗部门，这距离两个部门重组不过半年多时间。荷兰莱顿杨森制药有2500名员工，其中四分之一就职于传染病和疫苗部门，据悉，杨森只会保留研发大肠杆菌预防疫苗并继续提供艾滋病产品，其余全部退出。据Fierce Biotech长期跟踪的最新数据显示...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2361696532?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-08-24 21:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2361696532","market":"us","top_or_hot":-1,"title":"巨头关闭疫苗部门？多家知名药企大幅裁员","media":"虎嗅网","content":"<div>\n<p>8月23日，美国癌症免疫疗法公司Agenus 宣布计划裁员25%，并大幅缩减癌症药物研究。就在同一天，有报道称，强生旗下的杨森制药打算关闭位于荷兰莱顿的传染病和疫苗部门，这距离两个部门重组不过半年多时间。荷兰莱顿杨森制药有2500名员工，其中四分之一就职于传染病和疫苗部门，据悉，杨森只会保留研发大肠杆菌预防疫苗并继续提供艾滋病产品，其余全部退出。据Fierce Biotech长期跟踪的最新数据显示...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308242155058432ccd1&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>巨头关闭疫苗部门？多家知名药企大幅裁员</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n巨头关闭疫苗部门？多家知名药企大幅裁员\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-24 21:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308242155058432ccd1&s=b><strong>虎嗅网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月23日，美国癌症免疫疗法公司Agenus 宣布计划裁员25%，并大幅缩减癌症药物研究。就在同一天，有报道称，强生旗下的杨森制药打算关闭位于荷兰莱顿的传染病和疫苗部门，这距离两个部门重组不过半年多时间。荷兰莱顿杨森制药有2500名员工，其中四分之一就职于传染病和疫苗部门，据悉，杨森只会保留研发大肠杆菌预防疫苗并继续提供艾滋病产品，其余全部退出。据Fierce Biotech长期跟踪的最新数据显示...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308242155058432ccd1&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2133065610.SGD","symbol_name":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308242155058432ccd1&s=b","article_id":"2361696532","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308242155058432ccd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2361696532","pubTimestamp":1692885060,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"就在同一天，有报道称，强生旗下的杨森制药打算关闭位于荷兰莱顿的传染病和疫苗部门，这距离两个部门重组不过半年多时间。巨头也“受挫”今年上半年，强生的新冠疫苗收入下滑了近50%，传染病部门也就成为杨森制药唯一出现两位数收入下滑的板块。这可能是强生下定决心“关闭”传染病和疫苗部门的重要原因。2022年底，强生悄悄关闭了唯一可用于生产新冠疫苗的工厂，正是此次传出裁员传闻的荷兰莱顿杨森的工厂。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","BK4592":"伊斯兰概念","BK4504":"桥水持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","BK4559":"巴菲特持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","PFE":"辉瑞","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4550":"红杉资本持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4588":"碎股","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4007":"制药","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","JNJ":"强生","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4532":"文艺复兴科技持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4534":"瑞士信贷持仓","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"Giant closes vaccine division? Many well-known pharmaceutical companies have laid off employees substantially","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.6,"JNJ":0.9},"content_text":"8月23日，美国癌症免疫疗法公司Agenus 宣布计划裁员25%，并大幅缩减癌症药物研究。就在同一天，有报道称，强生旗下的杨森制药打算关闭位于荷兰莱顿的传染病和疫苗部门，这距离两个部门重组不过半年多时间。荷兰莱顿杨森制药有2500名员工，其中四分之一就职于传染病和疫苗部门，据悉，杨森只会保留研发大肠杆菌预防疫苗并继续提供艾滋病产品，其余全部退出。据Fierce Biotech长期跟踪的最新数据显示，今年只过去不到9个月，宣布裁员的生物制药公司数量已经与2022年全年总数相持平，达到119家。新药研发困难、竞争加剧，原本还信誓旦旦开发新品种的外资药企们纷纷走上裁员、砍管线的路，甚至有一批药企倒在了黎明前。巨头也“受挫”今年上半年，强生的新冠疫苗收入下滑了近50%，传染病部门也就成为杨森制药唯一出现两位数收入下滑的板块。这可能是强生下定决心“关闭”传染病和疫苗部门的重要原因。杨森主要专注免疫疾病、抗肿瘤、心血管及代谢疾病等研发管线，其中传染病和疫苗业务主要聚焦艾滋病病毒、乙肝，以及埃博拉、寨卡和结核病（TB）等。据7月20日强生发布的第二季度财报，其正在开发的药物已经不再包括乙肝、丁肝、流感和超长效HIV药物管线。自今年第一季度以来，强生已剔除了7个传染病项目，其中大多数是治疗乙肝的，这些管线都在杨森旗下。另外，几款疫苗也命途多舛：去年5月，杨森终止继续开发针对乙型肝炎病毒和人类乳头瘤病毒的潜在疫苗。在强生的疫苗管线中，最受关注的是新冠疫苗和RSV（呼吸道合胞病毒）疫苗。2021年由杨森研发的新冠疫苗获批FDA紧急使用。但很快因为疫苗工厂出现生产事故、卫生条件不合格等严重问题，1500万剂强生新冠疫苗受污染并被迫销毁；之后又有接种者出现“罕见而严重”的血栓等问题，强生疫苗基本没有实现市场预期。2022年底，强生悄悄关闭了唯一可用于生产新冠疫苗的工厂，正是此次传出裁员传闻的荷兰莱顿杨森的工厂。强生的新冠疫苗没成功，RSV疫苗也在今年3月29日终止了三期临床。RSV疫苗是强生花费九年时间，经过十几项临床试验、上万名受试者入组，投入数十亿美元研发的重磅产品，却在临上市的时候宣布失败，十分可惜。公司方面称，这一决定是在“对其投资组合进行审查”之后做出的。实际上，强生的研发速度还是不够快，就在今年5月，FDA相继批准了GSK和辉瑞的RSV疫苗上市。强生无意再卷入这样的内卷式竞争。裁员浪潮下对于许多药企来说，裁员并不是第一波，甚至不是第二波。例如，专注于DNA医学的Inovio最近宣布了13个月内的第三轮裁员，仅在 2023 年就重复削减的公司包括Molecular Templates、EQRx等。除了中小型生物药企，不乏知名巨头赛诺菲、拜耳、辉瑞、BMS等。今年赛诺菲在印度的两个疫苗生产基地裁员约800人；安进公司宣布计划裁员450人；辉瑞加州裁员196人；武田管线调整削减186人等。对于这些不差钱的巨头来说，一旦研发不理想或销售不达预期，就该省省该裁裁，属于常规操作，没有丝毫犹豫。裁员背后，是这些药企巨头面对新药研发困难、竞争加剧等压力下不得不做出的转变。今年以来，就有不少药企相继宣布终止在研管线。比如赛诺菲结束了BTK抑制剂atuzabrutinib 的开发，停止度普利尤单抗的过敏性真菌性鼻炎和无鼻息肉的慢性鼻窦炎两个项目；GSK结束对细胞基因疗法领域的投入；武田终止AAV基因疗法；诺华则砍去了在研管线中10%的非核心项目等等。此外，除了在研管线，产品销售不理想也成为药企精简团队的重要原因。此前，渤健宣布实施“Fit for Growth”计划，目标是在2025年前节省10亿美元运营费用。根据渤健最新发布的中报显示，上半年公司净利润大幅下滑23.2%。其中，多发性硬化症产品销售额同比下滑15%；脊髓性肌萎缩产品仅同比微增1%。在药企业绩有压力的时候，通过缩减成本而提高利润是普遍做法，也是保证利润一个最直接的做法。但是对于一些小型生物制药企业来说，却是“生死关”，今年以来已经有一大批宣布破产。5月14日，纳斯达克上市药企Athenex宣布破产，公司认为是新药监管障碍，以及“具有挑战性的生物技术市场和艰难的经济环境”导致公司破产。再早一些时候， 美国数字疗法企业Pear Therapeutics也申请破产保护；创立于2010年的Calithera Biosciences决定解散清算。全球生物医药企业的日子都不好过，中小药企更难熬。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2361696532","isCrawlerRequest":true}